These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20590033)

  • 21. [Hepatic minimal encephalopathy. The most frequently overlooked, clinically occult "metabolic syndrome" on the cirrhosis patient].
    Eisenburg J
    Fortschr Med; 1996 Apr; 114(12):141-6. PubMed ID: 8682429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
    Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
    Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
    Butterworth RF
    Drugs; 2019 Feb; 79(Suppl 1):1-3. PubMed ID: 30706421
    [No Abstract]   [Full Text] [Related]  

  • 24. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.
    Pérez Hernández JL; Higuera de la Tijera F; Serralde-Zúñiga AE; Abdo Francis JM
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S66-9. PubMed ID: 22228885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy.
    Kircheis G; Wettstein M; Dahl Sv; Häussinger D
    Metab Brain Dis; 2002 Dec; 17(4):453-62. PubMed ID: 12602521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [On the therapy of liver diseases with ornithine aspartate].
    Melzer H; Weber D; Wotzka R
    Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
    [No Abstract]   [Full Text] [Related]  

  • 27. Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy.
    Zhu GQ; Shi KQ; Huang S; Wang LR; Lin YQ; Huang GQ; Chen YP; Braddock M; Zheng MH
    Aliment Pharmacol Ther; 2015 Apr; 41(7):624-35. PubMed ID: 25684317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathogenesis and therapy of exogenous hepatic coma].
    Leonhardt H
    Fortschr Med; 1973 Jan; 91(1):35-8. PubMed ID: 4699340
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatic encephalopathy in a dog.
    Feldman EC
    Mod Vet Pract; 1978 Apr; 59(4):257-61. PubMed ID: 634269
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful treatment of hepatic encephalopathy in a patient with acute lymphoblastic leukemia.
    Dada R; Wilop S; Jost E; Galm O; Gassler N; Osieka R
    Acta Haematol; 2009; 122(4):216-20. PubMed ID: 19887778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ornicetil on encephalopathy. Effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease.
    Chainuvati T; Plengvanit U; Viranuvatti V
    Acta Hepatogastroenterol (Stuttg); 1977 Dec; 24(6):434-9. PubMed ID: 602619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ornithine aspartate and naloxone combined therapy for hepatic encephalopathy affects cognitive function, prognosis, and neuropeptide levels].
    Zhou ZW; Zhong XN; Zhou BY; Xiang JF; Wang RH; Yi J
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):385-8. PubMed ID: 24025143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
    Blanco Vela CI; Poo Ramírez JL
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pathognomonic significance of increased ammonia levels].
    Bosseckert H
    Dtsch Med Wochenschr; 1999 Mar; 124(10):300. PubMed ID: 10215430
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study.
    Jhajharia A; Singh S; Jana S; Ashdhir P; Nijhawan S
    Sci Rep; 2024 May; 14(1):11862. PubMed ID: 38789596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hepatic encephalopathy].
    Häussinger D
    Z Gastroenterol; 2002 Dec; 40 Suppl 2():43-5. PubMed ID: 12467007
    [No Abstract]   [Full Text] [Related]  

  • 38. [Critical study of venous blood ammonia in hepatic coma. Diagnosis, surveillance and treatment].
    Dupuy R; Thiroloix J
    Rev Int Hepatol; 1967; 17(1):43-53. PubMed ID: 6060728
    [No Abstract]   [Full Text] [Related]  

  • 39. [Amino acids prevent hepatic encephalopathy. Ornithine-aspartate in hyperammonemia--results of a study].
    Hartung HD
    Fortschr Med; 1989 Mar; 107(8):56. PubMed ID: 2651255
    [No Abstract]   [Full Text] [Related]  

  • 40. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.